Given the dismal prognosis of patients with glioblastoma and the lack of therapeutic options for many primary central nervous system tumors, some neuro-oncologists are using off-label RAF and MEK combination treatment for patients with recurrent high-grade glioma [11,12,13,14]. This evidence concerns the gene MAP2K7 and glioma.